These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23537458)

  • 21. Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States.
    Lee WC; Conner C; Hammer M
    Clin Ther; 2010 Sep; 32(10):1756-67. PubMed ID: 21194600
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
    Davies M; Pratley R; Hammer M; Thomsen AB; Cuddihy R
    Diabet Med; 2011 Mar; 28(3):333-7. PubMed ID: 21309842
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
    Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
    Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the Cost of Bringing People with Type 2 Diabetes Mellitus to Multiple Targets of Treatment in Canada.
    Skovgaard R; Jon Ploug U; Hunt B; Valentine WJ
    Clin Ther; 2015 Aug; 37(8):1677-88. PubMed ID: 26186809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial.
    Pratley R; Nauck M; Bailey T; Montanya E; Cuddihy R; Filetti S; Garber A; Thomsen AB; Hartvig H; Davies M;
    Int J Clin Pract; 2011 Apr; 65(4):397-407. PubMed ID: 21355967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK.
    Johansen P; Sandberg A; Capehorn M
    Adv Ther; 2020 Mar; 37(3):1248-1259. PubMed ID: 32048148
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of switching from sitagliptin to liraglutide in subjects with type 2 diabetes (LIRA-SWITCH): a randomized, double-blind, double-dummy, active-controlled 26-week trial.
    Bailey TS; Takács R; Tinahones FJ; Rao PV; Tsoukas GM; Thomsen AB; Kaltoft MS; Maislos M
    Diabetes Obes Metab; 2016 Dec; 18(12):1191-1198. PubMed ID: 27381275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials.
    Franch-Nadal J; Malkin SJP; Hunt B; Martín V; Gallego Estébanez M; Vidal J
    Adv Ther; 2022 Jul; 39(7):3180-3198. PubMed ID: 35553372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis.
    Pinelli NR; Hurren KM
    Ann Pharmacother; 2011 Jul; 45(7-8):850-60. PubMed ID: 21730278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Kirkman MS; Tripputi M; Krause-Steinrauf H; Bebu I; AbouAssi H; Burch H; Duran-Valdez E; Florez H; Garvey WT; Hsia DS; Salam M; Pop-Busui R;
    Diabetes Care; 2024 Apr; 47(4):594-602. PubMed ID: 38194519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes.
    Raz I; Chen Y; Wu M; Hussain S; Kaufman KD; Amatruda JM; Langdon RB; Stein PP; Alba M
    Curr Med Res Opin; 2008 Feb; 24(2):537-50. PubMed ID: 18194595
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.
    Olansky L; Reasner C; Seck TL; Williams-Herman DE; Chen M; Terranella L; Mehta A; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2011 Sep; 13(9):841-9. PubMed ID: 21535346
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes.
    Dobs AS; Goldstein BJ; Aschner P; Horton ES; Umpierrez GE; Duran L; Hill JS; Chen Y; Golm GT; Langdon RB; Williams-Herman DE; Kaufman KD; Amatruda JM; Ferreira JC
    J Diabetes; 2013 Mar; 5(1):68-79. PubMed ID: 22742523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy.
    Rigby SP; Handelsman Y; Lai YL; Abby SL; Tao B; Jones MR
    Endocr Pract; 2010; 16(1):53-63. PubMed ID: 19789153
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.
    Rhee EJ; Lee WY; Min KW; Shivane VK; Sosale AR; Jang HC; Chung CH; Nam-Goong IS; Kim JA; Kim SW;
    Diabetes Obes Metab; 2013 Jun; 15(6):523-30. PubMed ID: 23320436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.
    Fonseca V; Staels B; Morgan JD; Shentu Y; Golm GT; Johnson-Levonas AO; Kaufman KD; Goldstein BJ; Steinberg H
    J Diabetes Complications; 2013; 27(2):177-83. PubMed ID: 23116881
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA.
    Hunt B; Mocarski M; Valentine WJ; Langer J
    J Med Econ; 2017 Jul; 20(7):663-670. PubMed ID: 28294641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.